Department of Biotechnology, Delhi Technological University, Main Bawana Road, New Delhi, 110042, India.
Clin Exp Med. 2023 Dec;23(8):4297-4322. doi: 10.1007/s10238-023-01201-2. Epub 2023 Oct 7.
Through improving the immune system's ability to recognize and combat tumor cells as well as its receptivity to changes in the tumor microenvironment, immunotherapy has emerged as a highly successful addition to the treatment of cancer. However, tumor heterogeneity poses a significant challenge in cancer therapy as it can undermine the anti-tumor immune response through the manipulation of the extracellular matrix. To address these challenges and improve targeted therapies and combination treatments, the food and drug administration has approved several immunomodulatory antibodies to suppress immunological checkpoints. Combinatorial therapies necessitate the identification of multiple targets that regulate the intricate communication between immune cells, cytokines, chemokines, and cellular responses within the tumor microenvironment. The purpose of this study is to provide a comprehensive overview of the ongoing clinical trials involving immunomodulatory antibodies in various cancer types. It explores the potential of these antibodies to modulate the immune system and enhance anti-tumor responses. Additionally, it discusses the perspectives and prospects of immunomodulatory therapeutics in cancer treatment. Although immunotherapy shows great promise in cancer treatment, it is not exempt from side effects that can arise due to hyperactivity of the immune system. Therefore, understanding the intricate balance between immune activation and regulation is crucial for minimizing these adverse effects and optimizing treatment outcomes. This study aims to contribute to the growing body of knowledge surrounding immunomodulatory antibodies and their potential as effective therapeutic options in cancer treatment, ultimately paving the way for improved patient outcomes and deepening our perception of the intricate interactivity between the immune system and tumors.
通过提高免疫系统识别和对抗肿瘤细胞的能力以及对肿瘤微环境变化的接受能力，免疫疗法已成为癌症治疗的一项非常成功的补充手段。然而，肿瘤异质性在癌症治疗中构成了重大挑战，因为它可以通过操纵细胞外基质来破坏抗肿瘤免疫反应。为了应对这些挑战并改善靶向治疗和联合治疗，食品和药物管理局已经批准了几种免疫调节剂抗体来抑制免疫检查点。联合治疗需要确定多个调节免疫细胞、细胞因子、趋化因子和肿瘤微环境中细胞反应之间复杂通信的靶点。本研究旨在全面概述各种癌症类型中涉及免疫调节剂抗体的正在进行的临床试验。它探讨了这些抗体调节免疫系统和增强抗肿瘤反应的潜力。此外，它还讨论了免疫调节治疗在癌症治疗中的观点和前景。虽然免疫疗法在癌症治疗中显示出巨大的前景，但它也不能免除由于免疫系统过度活跃而产生的副作用。因此，了解免疫激活和调节之间的复杂平衡对于最大限度地减少这些不良反应并优化治疗结果至关重要。本研究旨在为围绕免疫调节剂抗体及其作为癌症治疗有效治疗选择的潜力的不断增长的知识体系做出贡献，最终为改善患者结局铺平道路，并加深我们对免疫系统和肿瘤之间复杂相互作用的认识。
